Últimas noticias sobre GE HealthCare Techs (NASDAQ:GEHC) Bolsa

GE HealthCare Techs

GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (54% of revenue), ultrasound (18%), patient care solutions (16%), and pharmaceutical diagnostics (12%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 44%, 26%, 14%, and 16% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (33% of revenue), pharmaceutical diagnostics (12%), and digital solutions (6%).

Earnings

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

COIN

FSLY

GEHC

HUBS

Wall Street anticipa importantes reportes financieros. Expectativas para Deere, Fastly, GE HealthCare y HubSpot y Coinbase.

Acciones a seguir en Wall Street hoy: Deere, Fastly, GE HealthCare y más

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Technologies Inc

Rumors

INCY

Watching Incyte Shares, Hearing M&A Blog Mentions Merck As Potential Buyer

Shares of Reddit Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) tanked in early trading on Thursday, despite the company reporting <a href="https://www.benzinga.com/general/social-media/25/02/43676199/reddit-q4-earnings-revenue-beat-eps-beat-shares-slide-as-user-growth-slows">upbeat fourth-quarter results</a>.
Here are some key analyst takeaways.
<ul>
<li>Piper Sandler <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5981fdcbc1f558000155e858/thomas-champion">analyst Thomas Champion</a> maintained an Overweight rating, while raising the price target from $197 to $210.</li>
<li>JMP Securities <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/598858a9803ad30001474c48/andrew-boone">analyst Andrew Boone</a> reiterated a Market Outperform rating, while lifting the price target from $190 to $200.</li>
<li>Needham <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/580607ae846faa000106ab43/laura-martin">analyst Laura Martin</a> maintained a Buy rating, while raising the price target from $190 to $220.</li>
<li>Goldman Sachs <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587e33195064ed000173030b/eric-sheridan">analyst Eric Sheridan</a> reiterated a Neutral rating, while lifting the price target from $176 to $185.</li>
<li>JPMorgan <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/591479b8290fa7000138e4b4/doug-anmuth">analyst Doug Anmuth</a> reiterated a Neutral rating, while cutting the price target from $142 to $185.</li>
</ul>
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Piper Sandler: Reddit delivered "another quarter of strong results," with revenues of $428 million, up 71% year-on-year and 23% sequentially, Champion said. "User growth remains solid with Global DAUs (daily active users) climbing to around 102 million on average in the fourth quarter, he added.
"Management highlighted the improvements to ML models including translating content via machine translation," the analyst wrote. The number of languages will expand from the current eight in 2025 and "is driving 40-50% of international user growth," he further wrote.
JMP Securities: Reddit reported DAU and revenue 2% and 5% above consensus, respectively, while EBITDA came in $23 million higher, Boone said. "However, the revenue beat tightened (vs. 3Q24) and U.S. DAUq declined Q/Q," he added.
The sequential decline in US DAUs "highlights the volatility of SEO as Reddit's goal of reaching 1B DAU seems further away after the quarter," the analyst wrote. The company has "multiple growth levers" that can support meaningful free cash flow ahead, he further stated.
Needham: Reddit's fourth-quarter revenue growth accelerated to 71% year-on-year from 62% in 2024, Martin said. Total ad revenues in the quarter reached $395 million, up 60% year-on-year, she added.
The company reported DAUs of 101.7 million, up 39% year-on-year and 5% sequentially, including 46% growth in international DAUs, the analyst stated. "AI-driven language translations should accelerate int&#8217;l DAU growth in FY25," she further wrote.
Goldman Sachs: Reddit's fourth-quarter results, which came in "solidly above the guided range," reflects continued operating momentum, Sheridan said. US DAUs came in below Street estimates due to Google traffic changes but this was offset by strong international user growth, he added.
Management's commentary was positive around "both the scope/impact of AI across the platform as well as continued progress on monetization in the coming years," the analyst stated. "Our conviction level in Reddit's ability to sustainably grow revenues well above industry average rates increased with this set of results," he further wrote.
JPMorgan: While DAU growth softened after Thanksgiving, this was due to a change in the Google search algorithm, Anmuth said. "The search traffic headwinds did not impact either logged in user growth or the fourth-quarter revenue, and the company indicated that search traffic has recovered so far in the first quarter, he added.
"Despite DAUq headwinds, Reddit continues to execute well &amp; capture share of advertiser budgets," the analyst wrote. Strong revenue growth and improved cost leverage supported strong profit gains, with Reddit growing revenue around 4.2 times faster than non-GAAP expenses in 2024, he further stated.
Price Action: Shares of Reddit had declined by 5.53% to $204.50 at the time of publication on Thursday.
Read More:<a href="https://www.benzinga.com/25/02/43485175/amd-alphabet-snap-chipotle-and-tesla-why-these-5-stocks-are-on-investors-radars-today"></a> 
<ul>
<li><a href="https://www.benzinga.com/25/02/43697537/robinhood-gilead-sciences-crocs-lincoln-electric-hubspot-ge-healthcare-and-other-big-stocks-moving-higher-on-thursday">Reddit CEO Acknowledges Google Search Update&#8217;s Impact On Traffic But Shrugs It Off: &#8216;These Changes Happen All The Time&#8217;</a></li>
</ul>
Image: Shutterstock

Analyst Color

Earnings Beats

Social Media

Price Target

Reiteration

Analyst Ratings

Movers

RDDT

Reddit Posts Solid Q4, Analysts Expect AI Language Translations To Grow Daily Active Users

Upwork Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPWK#NASDAQ">UPWK</a>) shares are <a target="_blank" href="http://benzinga.com/news/earnings/25/02/43678290/upwork-shares-rise-on-strong-q4-earnings-we-are-poised-to-continue-to-gain-market-share" rel="noreferrer noopener">trading higher on Thursday.</a>
The company&#8217;s total revenue increased 4% year-over-year. Active clients totaled 832,000 at quarter&#8217;s end. Gross services volume per active client came in at $4,815, up 1% year-over-year.
Upwork expects first-quarter revenue to be in the range of $186 million to $191 million. The company anticipates first-quarter adjusted earnings of 24 cents to 26 cents per share.
Here are the analysts&#8217;<a target="_blank" href="https://www.benzinga.com/quote/UPWK/analyst-ratings" rel="noreferrer noopener"> takes on the stock:</a>
<ul>
<li>RBC Capital Markets analyst Brad Erickson reiterated the Sector Perform rating on Upwork, raising the price forecast to $18 from $16.</li>
<li>Needham analyst Bernie Mcternan maintained the Buy rating on the stock, raising the price forecast to $19 from $17.</li>
<li>Piper Sandler analyst Matt Farrell reiterated the Overweight rating on the company, with a price forecast of $18.</li>
</ul>
See Also:&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/43676276/robinhood-q4-earnings-highlights-record-revenue-eps-beat-analyst-estimates-crypto-revenue-up-700" rel="noreferrer noopener">Robinhood Q4 Earnings Highlights: Record Revenue, EPS Beat Analyst Estimates, Crypto Revenue Up 700%+</a>
RBC Capital Markets: The analyst notes that while Enterprise revenue is showing positive growth with improvements in key metrics, including a 13% year-over-year increase in take rates, there is also a positive impact from AI.
However, the analyst writes that GSV is still declining, and a recovery might depend on macroeconomic factors, as other initiatives may not have an effect until 2026.
Erickson raises estimates, but remains cautious about giving a more positive rating until clearer signals of long-term growth are seen. The analyst raised the FY25 adjusted EBITDA estimate to $187.5 million from $176.5 million.
Needham: The analyst sees a slow macro environment in 2025, with lower take rate benefits and a decline in GSV and revenue year-over-year. The company plans to focus on AI, Enterprise, and Ads &amp; monetization in this investment year, aiming for growth in 2026 and beyond.
Despite these challenges, the analyst models an 8% growth in adjusted EBITDA, driven by 250 basis points of margin expansion, which remains a strong element of the Upwork story while waiting for macro conditions to improve.
The analyst is raising FY25 revenue and adjusted EBITDA estimates by 3% and 9%, respectively, due to higher take rate assumptions, though slightly offset by lower GSV expectations.
This adjustment follows the company&#8217;s better-than-expected performance in the fourth quarter, with revenue exceeding expectations by 6% and adjusted EBITDA by 25%.
Piper Sandler: The analyst notes that Upwork is concentrating on controllable factors, investing in AI, enterprise, and ads/monetization for growth.
Farrell remains impressed with the company&#8217;s ability to expand EBITDA margins, aiming for 35% over the next five years. Overall, per the analyst, estimates are likely to rise, assuming no significant changes in the macro environment.
Price Action: UPWK shares are trading higher by 7.08% to $16.63 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43694603/hertz-misses-on-revenue-profit-as-fleet-shrinks-costs-weigh" target="_blank" rel="noreferrer noopener">Hertz Misses On Revenue, Profit As Fleet Shrinks, Costs Weigh</a></li>
</ul>
Photo via Shutterstock.

Equities

General

UPWK

Upwork Gains On AI And Enterprise Growth, But Analysts See Macro Challenges Limiting Upside

On Wednesday,&nbsp;CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) reported fourth-quarter sales of $97.71 billion, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $97.19 billion</a>.
Total revenues increased 4.2%, driven by growth in the Health Care Benefits and Pharmacy &amp; Consumer Wellness segments, partially offset by a decline in the&nbsp;<a target="_blank" href="https://www.benzinga.com/25/02/43655820/cvs-health-stock-surges-on-better-than-expected-q4-earnings-upbeat-annual-outlook" rel="noreferrer noopener">Health Services segment</a>.
The Medical benefit ratio increased from 88.5% to 94.8% compared to the prior year, driven by increased utilization, the unfavorable impact of the previously disclosed decline in the company&#8217;s Medicare Advantage star ratings for the 2024 payment year, and the impact of higher acuity in Medicaid.
Truist analyst noted that CVS Health&#8217;s fourth-quarter results were mostly better than expected, and the company provided strong guidance for 2025.
In its business segments, revenue projections for Health Services and Pharmacy &amp; Consumer exceeded expectations. However, the Health Care Benefits (HCB) segment fell short due to lower-than-expected membership growth.
Meanwhile, the medical benefit ratio (MBR) is expected to improve by 1 percentage point year-over-year, reaching at least 91.5%, which aligns with prior estimates and is slightly better than the 92.0% consensus.
Analyst David MacDonald writes CVS expects its Medicare Advantage (MA) margins to improve in 2025 from the negative 4.5% to 5.0% range seen in 2024, though they won&#8217;t break even yet. Management reaffirmed their long-term goal of a 3% to 5% margin.
For the overall business, CVS projects Health Care Benefits (HCB) margins to reach 1.5% in 2025, significantly lower than 5%+ in 2023 and 7% in 2022.
Management noted that each percentage point of HCB margin improvement adds about $0.75 to adjusted EPS, implying a $3 to $4 earnings boost if margins return to target levels over time.
<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41279374/cvs-health-positioned-for-medicare-margin-expansion-and-market-share-gains-says-bar" rel="noreferrer noopener">CostVantage is gaining traction</a>, with all commercial contracts using the model as of January 1, Truist writes. The company is also developing a cost-based approach for Medicare and Medicaid.
For 2025, revenue is projected to reach at least $134 billion, surpassing the previous estimate of $128 billion, driven by slightly higher prescription volumes (1.77 billion vs. 1.74 billion previously expected). The company sees 2025 as a transition year for CostVantage, with stronger growth potential in the future.
Finally, while leverage remains above the company&#8217;s long-term target, Truist expects better operational performance, especially at Aetna, to drive improvement over time.
The analyst maintains the Buy rating with an increased price forecast of <a target="_blank" href="https://www.benzinga.com/quote/CVS/analyst-ratings" rel="noreferrer noopener">$76, up from $60</a>.
Other analyst reactions:
<ul>
<li>Leerink Partners upgrades CVS Health to Outperform rating, raising the price forecast to $75.</li>
<li>Barclays analyst Andrew Mok maintains CVS Health with an Overweight rating, raising the price forecast from $71 to $73.</li>
<li>Wells Fargo analyst Stephen Baxter maintains the Overweight rating on CVS Health while raising the price forecast from $68 to $73.</li>
</ul>
Price Action: CVS stock is up 5.77% at $66.97 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43692752/brewing-company-molson-coors-q4-gets-boost-from-higher-pricing-stock-rises" target="_blank" rel="noreferrer noopener">Brewing Company Molson Coors Q4 Gets Boost From Higher Pricing, Stock Rises</a></li>
</ul>
Photo by Around the World Photos via Shutterstock

Large Cap

Upgrades

Health Care

CVS Health Gains Momentum After Q4 Performance, Analyst Upgrades Stock

Macro Economic Events

Commodities

Economics

Trump Will Meet With US Steel; Says Steel Tariffs Have Given US Steel More Power

Looking into the current session, WillScot Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSC#NASDAQ">WSC</a>) shares are trading at $37.78, after a 2.52% increase. Moreover, over the past month, the stock increased by 3.31%, but in the past year, decreased by 24.65%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1739475911_0.png" alt="Past Year Chart" />

<h3>How Does WillScot Holdings P/E Compare to Other Companies?</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of 35.91 in the Construction &amp; Engineering industry, WillScot Holdings Inc. has a higher P/E ratio of 307.08. Shareholders might be inclined to think that WillScot Holdings Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1739475911_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

P/E Ratio Insights for WillScot Holdings

WIIM

Bloom Energy shares are trading higher after the company announced a carbon capture partnership with Chart Industries.

Cardano (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>) has jumped 12% in seven days, fueled by Grayscale's application for the <a href="https://www.benzinga.com/25/02/43613700/cardano-outgains-bitcoin-ethereum-with-11-rally-after-its-first-ever-spot-etf-application-in-the-us">first spot ETF</a>.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Cardano (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>)</td>
<td>&nbsp;$0.8003</td>
<td>$28.2 billion</td>
<td>+2.5%&nbsp;</td>
<td>+12.6%&nbsp;</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$2,636.30</td>
<td>$317.7 billion</td>
<td>-1.5%</td>
<td>-2.2%&nbsp;</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.2566&nbsp;</td>
<td>$37.9 billion</td>
<td>-1.2%&nbsp;</td>
<td>+4%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: More Crypto Online foresees a bullish outlook as long as ADA stays above $0.684, with $0.65–$0.56 as the key lower support zone if broken.
A move above the February high would signal a push toward the $0.87–$0.94 Fibonacci extension.
While recent gains may be fuelled by ETF optimism, price action remains within corrective structures, warranting caution until key levels confirm a trend.
Crypto chart analyst Ali Martinez believes Cardano is likely repeating the same pattern from 2020 to 2021 at a slower pace. He predicts this could lead to a parabolic rally.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Looking back at history, <a href="https://twitter.com/hashtag/Cardano?src=hash&amp;ref_src=twsrc%5Etfw">#Cardano</a> <a href="https://twitter.com/search?q=%24ADA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$ADA</a> seems to be repeating the same pattern from 2020 to 2021 at a slower pace, which could soon lead to a parabolic rally! Go to <a href="https://twitter.com/SimpleFXcom?ref_src=twsrc%5Etfw">@SimpleFXcom</a> via my link <a href="https://t.co/GLjkpQvNJr">https://t.co/GLjkpQvNJr</a>, claim the $5,000 bonus, and get some before it&#39;s too late! <a href="https://t.co/5aJn6aQjKC">pic.twitter.com/5aJn6aQjKC</a>
&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1889784292299219321?ref_src=twsrc%5Etfw">February 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Statistics: In a post on x on Wednesday, Santiment data shows Cardano's market cap having risen 11% despite a broader crypto retrace. 
Whales and sharks holding at least 1 million ADA have been accumulating since November 2023, adding 1.41 billion coins (2.35% of supply) over 15 months. 
Amid volatility, ADA&#8217;s <a href="https://x.com/santimentfeed/status/1889431054236172506">price</a> has surged 107% during this accumulation cycle. 
Martinez <a href="https://x.com/ali_charts/status/1890019592590012762">noted</a> that whales moved more than 70 million ADA in the past 96 hours.
Cardano has also dominated crypto discussions, with Ethereum and Dogecoin nearly absent from social chatter. 
Meanwhile, Bitcoin <a href="https://x.com/santimentfeed/status/1889448216875217103">remains</a> the most talked-about asset.
IntoTheBlock data shows Cardano's large transaction volume dropped 8.2% while daily active addresses increased 0.2%.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/02/43613700/cardano-outgains-bitcoin-ethereum-with-11-rally-after-its-first-ever-spot-etf-application-in-the-us">Cardano Outperforms Bitcoin, Ethereum With 11% Gains After Grayscale Applies For First Ever ADA Spot ETF In US</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ADA

$DOGE

$ETH

Cardano Jumps 12% In 7 Days: Why Is ADA Going Up?

Robinhood Markets Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) analysts on Thursday raised price targets on Robinhood shares following the company&#8217;s fourth-quarter results. Analysts are overwhelmingly impressed with profitability metrics combined with <a href="https://www.benzinga.com/news/earnings/25/02/43676276/robinhood-q4-earnings-highlights-record-revenue-eps-beat-analyst-estimates-crypto-revenue-up-700">accelerating growth</a>. 
Q4 Results: Robinhood reported a strong fourth quarter, with revenue of $1.01 billion coming in ahead of&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">estimates</a>&nbsp;of $944.62 million, and earnings of $1.01 per share beating estimates of 42 cents per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Total revenue was up 115% year-over-year, driven by strong transaction-based revenue growth across equities, options and cryptocurrency. Robinhood said net deposits hit a record of $16.1 billion in the quarter as accounts grew 10%. 
KeyBanc Maintains Overweight: Keybanc analyst Steve Barger maintained an <a href="https://www.benzinga.com/analyst-stock-ratings">Overweight rating</a> and raised the price target from&nbsp;$57&nbsp;to&nbsp;$75, citing improving profitability and momentum with key product initiatives.
The Keybanc analyst believes Robinhood is poised to continue its leadership in the financial application space and grow average revenue per user on the back of strong engagement, rapid uptake of new products, continued innovation and a maturing culture focused on responsible, profitable growth. 
&#8220;As a well-known and culturally relevant brand, Robinhood is well positioned to make further in-roads within the targeted segment across various financial products,&#8221; Barger said.
JMP Securities Maintains Market Outperform: JMP Securities analyst Devin Ryan maintained a Market Outperform and raised the price target from&nbsp;$60&nbsp;to&nbsp;$77, calling it a &#8220;blowout quarter&#8221; for Robinhood. 
&#8220;Robinhood is currently operating with tremendous momentum, and we see elevated growth persisting across virtually all aspects of its business, not to mention it is entering a number of new markets over the next year that are promising, and we envision incremental areas for innovation still to come beyond those,&#8221; the JPM Securities analyst said.
While Robinhood is seeing an acceleration in revenue, the company also remains focused on profitability, which Ryan expects to help support further margin expansion. The analyst noted that there are several growth drivers on the product roadmap that are not yet being accounted for in Street estimates.
Needham Maintains Buy: Needham analyst John Todaro maintained a Buy rating and raised the price target from&nbsp;$52&nbsp;to&nbsp;$70 after the company posted a &#8220;strong beat and solid outlook.&#8221;
Todaro echoed the sentiment of JMP&#8217;s Ryan, noting that Robinhood was able to maintain expense discipline and reach 60% EBITDA margins while reporting strong growth across all three transaction segments. 
&#8220;Robinhood is positioned to be a major beneficiary of more positive regulation within the crypto space, while emerging as a leader in its equity &amp; options offering via advanced trading product launches,&#8221; Todaro said.
&#8220;We expect HOOD to launch a number of new crypto related products, in particular those that appeal to a retail customer base, in 2025, which should allow the company to take share from centralized and decentralized peers.&#8221;
Check This Out: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43697803/robinhoods-crypto-bet-pays-off-bernstein-predicts-massive-growth-105-price-target">Robinhood&#8217;s Crypto Bet Pays Off: Bernstein Predicts Massive Growth, $105 Price Target</a>
Goldman Sachs Maintains Buy: Goldman Sachs analyst James Yaro maintained a Buy rating and raised the price target from $54 to $62, calling it a &#8220;well-rounded quarter&#8221; for Robinhood.
Goldman appears to be less optimistic than the aforementioned analysts, albeit not by much. The analyst expects Robinhood to continue rolling out new products that will help the company capture market share and expand globally. 
Given the stronger trends in the fourth quarter, Yaro raised the net revenue estimates for full-year 2025 by 11%. The analyst also bumped full-year adjusted earnings estimates by 15%.
JPMorgan Maintains Neutral: JPMorgan analyst Kenneth Worthington is the least bullish of the bunch. The analyst maintained a Neutral rating and raised the price target from&nbsp;$39&nbsp;to&nbsp;$45, suggesting downside from current levels.
&#8220;Robinhood's platform is clearly maturing and evidencing its profitability, but we remain cautious on unproven business lines and valuation,&#8221; Worthington said. 
Robinhood shares are up 67% year-to-date and the stock has climbed more than 360% over the past year. The JPMorgan analyst acknowledged the significant progress at Robinhood, but remains cautious on new products and the scale of the company versus larger competitors. Worthington is also skeptical on the profitability potential of Robinhood&#8217;s smaller accounts.
&#8220;While we acknowledge the significant growth Robinhood has delivered the past 3-4yr, we remain Neutral given the competitive environment and varied outlook,&#8221; Worthington said. 
JPMorgan&#8217;s $45 price target for December is based on a 32-times earnings multiple and $2 billion in excess cash. 
HOOD Price Action: <a href="http://benzinga.com/quote/hood" target="_blank" rel="noreferrer noopener">Robinhood shares</a> were up 13% at $63.14 at the time of writing Thursday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/02/43683255/robinhood-ceo-vlad-tenev-says-prediction-markets-are-the-future-amid-super-bowl-lix-suspension-and-missing-regulatory-clarity">Robinhood CEO Vlad Tenev Says &#8216;Prediction Markets Are The Future&#8217; Amid Super Bowl LIX Suspension And Missing &#8216;Regulatory Clarity&#8217;</a></li>
</ul>
Photo: Shutterstock.

HOOD

5 Robinhood Analysts React To 'Blowout' Q4 Earnings: Can The 'Tremendous Momentum' Continue?

Antero Midstream shares are trading after company reported better-than-expected Q4 financial results.

On Wednesday, Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) reported a fourth-quarter EPS loss of 64 cents, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus loss of 1.07 euros</a>.
Total revenue for the fourth quarter of 2024 was 173.9 million euros, beating the consensus of 111.178 million euros compared to 137.7 million <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43674382/ascendis-pharma-reports-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">euros reported a year ago</a>.
The increase was primarily due to Novo Nordisk A/S&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) $100 million upfront fee and the EU launch of Yorvipath.
TransCon hGH (lonapegsomatropin, marketed as Skytrofa) sales reached 58.5 million euros.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41723496/wegovy-manufacturer-inks-multi-million-deal-for-monthly-obesity-drug" rel="noreferrer noopener">Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug</a>
TransCon PTH (palopegteriparatide, marketed as Yorvipath) revenue for the fourth quarter of 2024 totaled €13.6 million.
The company reported a strong start to the U.S. Yorvipath launch, with 908 prescriptions as of February 7, 2025, and 539 unique prescribing health care providers.
As of December 31, 2024, cash and cash equivalents totaled 559.5 million euros. Including the $100 million upfront payment, cash at the end of 2024 would have totaled 655 million euros.
Concurrently, Ascendis Pharma's board authorized the repurchase of up <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43674574/ascendis-pharma-as-announces-share-repurchase-program-net-settlement-of-certain-rsus" rel="noreferrer noopener">to $18.25 million shares</a>.
Goldman Sachs analyst writes that Yorvipath has only been available in the U.S. for a few months, but early prescription trends have been strong and widespread. However, insurance coverage and reimbursement challenges may slow revenue growth in the short term.
Looking ahead, analyst Paul Choi writes investors will likely focus on the company's progress toward achieving breakeven cash flow and key milestones, including:
<ul>
<li>The pace of Yorvipath's rollout in the U.S. and EU</li>
<li>Data from the COACH study on achondroplasia, expected in Q2 2025</li>
<li>Regulatory discussions on Transcon CNP</li>
<li>Competitive updates from BioMarin Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) in achondroplasia and AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) in hypoparathyroidism.</li>
</ul>
With Yorvipath showing potential for a strong launch in 2025, Goldman Sachs maintains the Buy rating and raises the price target <a target="_blank" href="https://www.benzinga.com/quote/CVS/analyst-ratings" rel="noreferrer noopener">to $225 from $200</a>.
Price Action: ASND stock is up 15.8% at $146.08 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/02/43697905/zoetis-drops-as-2025-guidance-falls-short-of-estimates" target="_blank" rel="noreferrer noopener">Zoetis Drops As 2025 Guidance Falls Short Of Estimates</a></li>
</ul>

Biotech

Guidance

ASND

BMRN

Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?

Gold is trading higher following greater-than-expected January PPI figures.

<a href="https://www.benzinga.com/25/02/43682927/changpeng-cz-zhao-mulls-over-community-suggestion-of-a-dog-based-memecoin-pretty-interesting-how-things-work">Binance founder Changpeng Zhao</a>, known as &#8220;CZ,&#8221; ignited a meme coin frenzy and subsequent backlash in the crypto community after sharing a story and photos of his dog, a Belgian Malinois named Broccoli.
While CZ explicitly <a href="https://x.com/cz_binance/status/1890075311141974411">stated </a>he was not creating a meme coin himself, the post prompted the launch of hundreds of tokens bearing the dog&#8217;s name on the BNB Chain (CRYPTO: BSC).
What Happened: In his <a href="https://x.com/cz_binance/status/1890071433214038103">tweet</a>, CZ explained that he chose the name &#8220;Broccoli&#8221; because it starts with &#8220;B,&#8221; has some &#8220;green in it,&#8221; and has a &#8220;blocky sound, as in blockiichain.&#8221;
&#8220;Can&#8217;t get away from crypto, haha,&#8221; he added.
The resulting proliferation of &#8220;Broccoli&#8221; themed meme coins on BSC drew immediate criticism from some corners of Crypto Twitter. 
Twitter's crypto scene reacted with a mix of excitement, skepticism, and outright cynicism. 
Some traders saw it as another "BNB pump" orchestrated by CZ, while others joked that &#8220;Memecoin Supercasino Wars&#8221; had officially begun between BNB Chain and Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>). 
&#8220;Why stay on Solana when BNB Chain is getting pumped by CZ, arguably the most popular crypto influencer?&#8221; one user asked, highlighting the competitive landscape of speculative tokens.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43699338/opensea-launches-os2-platform-with-token-trading-and-sea-community-token">OpenSea Launches OS2 Platform With Token Trading And $SEA Community Token</a>
Others were less amused, with some traders accusing the entire space of running on recycled hype cycles. 
&#8220;Every new project these days is either a memecoin rug or a VC bukkake that nukes -90% within hours,&#8221; one post <a href="https://x.com/abetrade/status/1889815432682668083">read</a>. 
The reaction signifies growing frustration with the rapid, often short-lived nature of new meme coin trends, particularly those linked to high-profile figures in the industry.
Despite the controversy, the BNB Foundation hinted at potential incentives for Broccoli-themed tokens, suggesting that top-performing meme coins on BNB Chain could receive liquidity support or other rewards. While details remain unclear, the possibility of foundation-backed incentives has only fueled further speculation.
CZ's post is the latest in a growing trend where offhand comments by prominent figures lead to immediate financial speculation, often triggering a cascade of meme coin launches. 
Why It Matters: Similar events have unfolded before, with tokens being created around everything from Elon Musk's dog to absurd celebrity soundbites.
Despite the backlash, CZ hinted at potential support for the &#8220;Broccoli&#8221; meme coins, stating that &#8220;The BNB Foundation may provide rewards for the top memes on the BNB Chain, giving LP support or other rewards. The details are still being discussed. More to come.&#8221;
Notably, Zhao was released from a four-month prison sentence&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38547115/ex-binance-ceo-changpeng-zhao-sees-crypto-industry-entering-new-phase" target="_blank" rel="noreferrer noopener">for anti-money laundering violations</a> in September last year.
He was imprisoned for his role in failing to establish an effective anti-money laundering (AML)&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38401035/binance-founder-changpeng-zhao-apologizes-doj-pushes-for-3-year-sentence" target="_blank" rel="noreferrer noopener">program at the cryptocurrency exchange.</a>
He has since shifted his focus to educational initiatives, founding&nbsp;Giggle Academy, which aims to educate young people about <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38532677/former-binance-ceo-changpeng-zhao-sentenced-to-four-months-in-prison">cryptocurrency and blockchain technology.</a>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43697803/robinhoods-crypto-bet-pays-off-bernstein-predicts-massive-growth-105-price-target">Robinhood&#8217;s Crypto Bet Pays Off: Bernstein Predicts Massive Growth, $105 Price Target</a></li>
</ul>
Image: Shutterstock

$SOL

Binance Founder CZ Sidelines XRP, Solana And Sparks BNB Chain Meme Coin Frenzy With His Dog 'Broccoli'

Wall Street climbed on Thursday, even as the Producer Price Index (PPI) sharply exceeded estimates in January, reigniting concerns <a href="https://www.benzinga.com/economics/macro-economic-events/25/02/43692996/inflation-fears-mount-as-producer-prices-soar-to-35-put-fed-interest-rate-cut-on-ice">over persistent inflationary pressures. </a>
Despite the hotter-than-expected PPI reading—up 3.5% year-over-year in January, surpassing the 3.3% forecast—investors found some relief in certain PPI components that influence the Federal Reserve's preferred inflation gauge, which showed signs of <a href="https://www.benzinga.com/economics/macro-economic-events/25/02/43701823/economists-breathe-sigh-of-relief-why-producer-inflation-isnt-as-bad-as-it-seems">cooling compared to December.</a>
Investor risk appetite remained supported by expectations of ceasefire talks in Ukraine following a conversation between former President Donald Trump and Russian President Vladimir Putin a day earlier. 
By midday trading in New York, all major indices were in positive territory, with technology stocks leading the gains. Among semiconductor stocks, Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) continued to rally, surging 10% after strong performances in prior sessions. 
The U.S. chipmaker benefited from renewed buying momentum following comments from Vice President J.D. Vance, who indicated that the Trump administration plans to ease regulations to accelerate AI chip innovation in the U.S.
Intel has now soared over 27% this week, tracking its best weekly performance since 1974. 
The U.S. dollar extended its decline as Treasury yields pulled back sharply, reversing Wednesday&#8217;s surge.
In commodities, gold edged up 0.4% to $2,918 per ounce, oil remained steady at $71 per barrel, and natural gas surged 2.4% to $3.66 per million British thermal units. 
Sentiment in cryptocurrency markets remained subdued, with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) sliding 2.4% to trade below $96,000.
<h3 class="wp-block-heading">Thursday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,903.94</td>
<td>0.9%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,088.51</td>
<td>0.6%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,493.13</td>
<td>0.3%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,261.64</td>
<td>0.3%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:45 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;rose 0.6% to $606.89.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.3% to $445.18.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 0.9% to $532.98.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 0.4% to $224.58.</li>
<li>The&nbsp;Materials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) outperformed, up 1.1%; the&nbsp;Industrials Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>) lagged, down 1.2%.</li>
</ul>
<h3 class="wp-block-heading">Thursday&#8217;s Stock Movers</h3>
Stocks reacting to company earnings reports included:
<ul>
<li>Cisco Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>): up 2.05%</li>
<li>Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>): down 7.8%</li>
<li>Duke Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>): down 2.5%</li>
<li>American Electric Power Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>): down 0.6%</li>
<li>Equinix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>): down 1.9%</li>
<li>Moody's Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>): up 2.9%</li>
<li>Deere &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>): down 1.5%</li>
<li>PPL Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPL#NYSE">PPL</a>): down 1.8%</li>
<li>MGM Resorts International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>): up 17.9%</li>
<li>Paycom Software Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAYC#NYSE">PAYC</a>): flat</li>
<li>HubSpot Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>): up 1.6%</li>
<li>Lincoln Electric Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LECO#NASDAQ">LECO</a>): up 11.7%</li>
<li>Curtiss-Wright Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CW#NYSE">CW</a>): down 0.5%</li>
<li>West Pharmaceutical Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>): down 34%</li>
<li>CBRE Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>): up 1.1%</li>
<li>DTE Energy Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTE#NYSE">DTE</a>): up 2.4%</li>
<li>AppLovin Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>): up 19.9%</li>
<li>Reddit Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>): down 8.8%. </li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43703014/robert-f-kennedy-confirmed-as-trump-secretary-of-health">Robert F. Kennedy, Vaccine Skeptic, Confirmed As Trump&#8217;s Secretary Of Health: Health Care Stocks To Watch</a></li>
</ul>
Photo: Ryan DeBerardinis via Shutterstock

Bonds

Broad U.S. Equity ETFs

Econ #s

ETFs

$BTC

CBRE

CROX

CSCO

SPDR Dow Jones Industrial Average ETF Trust

EQIX

INTC

LECO

PAYC

Select Sector SPDR-Consumer Discretionary

ZBRA

Stocks Rise Despite Hot Producer Inflation, Intel Soars, Bitcoin Drops Below $96,000: What's Driving Markets Thursday?

Legal

PAYO

Payoneer Receives Regulatory Approval In China Required To Complete Acquisition Of A Payment Service Provider

Whales with a lot of money to spend have taken a noticeably bullish stance on GXO Logistics.
Looking at options history for GXO Logistics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GXO#NYSE">GXO</a>) we detected 16 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 37% with bearish.
From the overall spotted trades, 13 are puts, for a total amount of $932,843 and 3, calls, for a total amount of $122,227.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $22.5 to $50.0 for GXO Logistics over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for GXO Logistics's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across GXO Logistics's significant trades, within a strike price range of $22.5 to $50.0, over the past month.
<h3>GXO Logistics 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739475041_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GXO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$4.3</td>
<td>$3.3</td>
<td>$3.3</td>
<td>$40.00</td>
<td>$140.9K</td>
<td>3.2K</td>
<td>1.5K</td>
</tr>
<tr>
<td>GXO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$3.8</td>
<td>$3.7</td>
<td>$3.8</td>
<td>$40.00</td>
<td>$140.6K</td>
<td>3.2K</td>
<td>3.0K</td>
</tr>
<tr>
<td>GXO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$6.1</td>
<td>$5.9</td>
<td>$6.1</td>
<td>$42.50</td>
<td>$120.1K</td>
<td>1.4K</td>
<td>234</td>
</tr>
<tr>
<td>GXO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$4.0</td>
<td>$3.7</td>
<td>$3.7</td>
<td>$40.00</td>
<td>$78.8K</td>
<td>3.2K</td>
<td>18</td>
</tr>
<tr>
<td>GXO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$3.7</td>
<td>$3.6</td>
<td>$3.7</td>
<td>$40.00</td>
<td>$69.9K</td>
<td>3.2K</td>
<td>260</td>
</tr>
</tbody>
</table>

<h3>About GXO Logistics</h3>
GXO Logistics Inc is a contract logistics company. Its revenue is diversified across numerous verticals and customers, including many multinational corporations. It provides warehousing and distribution, order fulfillment, e-commerce, reverse logistics, and other supply chain services differentiated by its ability to deliver technology-enabled, customized solutions at scale. Geographically, it generates revenue from the United Kingdom, the United States, the Netherlands, France, Spain, Italy, and other countries, and derives the majority of its revenue from the United Kingdom.
<h3>Present Market Standing of GXO Logistics</h3>
<ul>
<li>Trading volume stands at 4,742,446, with GXO's price down by -15.7%, positioned at $36.05.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 82 days.</li>
</ul>
<h3>What The Experts Say On GXO Logistics</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $49.333333333333336.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Goldman Sachs persists with their Neutral rating on GXO Logistics, maintaining a target price of $54. 
&#x2A; An analyst from Barclays has decided to maintain their Equal-Weight rating on GXO Logistics, which currently sits at a price target of $45. 
&#x2A; Reflecting concerns, an analyst from Loop Capital lowers its rating to Hold with a new price target of $49.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for GXO Logistics with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Check Out What Whales Are Doing With GXO

Benzinga's options scanner just detected over 13 options trades for Credo Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) summing a total amount of $752,842.
At the same time, our algo caught 5 for a total amount of 483,525.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $65.0 to $95.0 for Credo Technology Group over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Credo Technology Group stands at 1050.12, with a total volume reaching 2,026.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Credo Technology Group, situated within the strike price corridor from $65.0 to $95.0, throughout the last 30 days.
<h3>Credo Technology Group 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739475035_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRDO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$38.1</td>
<td>$37.8</td>
<td>$37.8</td>
<td>$95.00</td>
<td>$196.5K</td>
<td>44</td>
<td align="right">53</td>
</tr>
<tr>
<td>CRDO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$31.0</td>
<td>$30.1</td>
<td>$30.1</td>
<td>$85.00</td>
<td>$165.5K</td>
<td>61</td>
<td align="right">55</td>
</tr>
<tr>
<td>CRDO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$10.4</td>
<td>$10.1</td>
<td>$10.3</td>
<td>$70.00</td>
<td>$82.4K</td>
<td>1.3K</td>
<td align="right">234</td>
</tr>
<tr>
<td>CRDO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$2.55</td>
<td>$2.0</td>
<td>$2.5</td>
<td>$75.00</td>
<td>$50.0K</td>
<td>3.2K</td>
<td align="right">390</td>
</tr>
<tr>
<td>CRDO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$17.6</td>
<td>$17.3</td>
<td>$17.31</td>
<td>$80.00</td>
<td>$43.2K</td>
<td>154</td>
<td align="right">25</td>
</tr>
</tbody>
</table>

<h3>About Credo Technology Group</h3>
Credo Technology Group Holding Ltd delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. It has a geographic presence in Hong Kong, the United States, Mainland China, Taiwan, and the Rest of the World.
<h3>Credo Technology Group's Current Market Status</h3>
<ul>
<li>With a volume of 2,407,209, the price of CRDO is down -2.0% at $69.92. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 19 days.</li>
</ul>
<h3>Expert Opinions on Credo Technology Group</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $90.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on Credo Technology Group, which currently sits at a price target of $90. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Credo Technology Group, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

CRDO

Credo Technology Group Unusual Options Activity

Investors with significant funds have taken a bearish position in DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), a development that retail traders should be aware of.
This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in DXCM usually indicates foreknowledge of upcoming events.
Today, Benzinga's options scanner identified 8 options transactions for DexCom. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 37% being bullish and 62% bearish. Of all the options we discovered, 7 are puts, valued at $421,287, and there was a single call, worth $49,500.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $80.0 to $87.5 for DexCom over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for DexCom's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of DexCom's whale activity within a strike price range from $80.0 to $87.5 in the last 30 days. 
<h3>DexCom Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739475030_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/14/25</td>
<td>$3.7</td>
<td>$3.5</td>
<td>$3.66</td>
<td>$84.00</td>
<td>$145.8K</td>
<td>83</td>
<td align="right">415</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/07/25</td>
<td>$5.3</td>
<td>$5.0</td>
<td>$5.1</td>
<td>$85.00</td>
<td>$86.6K</td>
<td>172</td>
<td align="right">0</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$15.4</td>
<td>$15.3</td>
<td>$15.4</td>
<td>$85.00</td>
<td>$53.9K</td>
<td>1.2K</td>
<td align="right">76</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$11.1</td>
<td>$10.9</td>
<td>$11.0</td>
<td>$80.00</td>
<td>$49.5K</td>
<td>1.4K</td>
<td align="right">74</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.3</td>
<td>$3.2</td>
<td>$3.2</td>
<td>$80.00</td>
<td>$48.0K</td>
<td>1.5K</td>
<td align="right">169</td>
</tr>
</tbody>
</table>

<h3>About DexCom</h3>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
<h3>Present Market Standing of DexCom</h3>
<ul>
<li>Currently trading with a volume of 3,574,013, the DXCM's price is up by 0.13%, now at $83.98. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 0 days.</li>
</ul>
<h3>Expert Opinions on DexCom</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $109.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Baird upgraded its action to Outperform with a price target of $104. 
&#x2A; An analyst from Redburn Atlantic has elevated its stance to Buy, setting a new price target at $115. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for DexCom with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

DXCM

DexCom Options Trading: A Deep Dive into Market Sentiment

On Wednesday,&nbsp;Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) reported fourth-quarter adjusted EPS of $3.44, up 17%, beating&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of $3.35</a>.
The company&nbsp;reported&nbsp;sales of&nbsp;$2.46 billion, up 2% year over year on constant currency and 3% on a reported basis, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43673992/biogen-delivers-q4-beat-analyst-focuses-on-leqembi-expansion-2025-outlook" rel="noreferrer noopener">consensus of $2.40 billion</a>.
Needham analyst Ami Fadia expects challenges in the multiple sclerosis segment, as growth from key product launches isn&#8217;t enough to make up for declines.
While Leqembi sales performed well outside the U.S. and Skyclarys is set to grow internationally, Medicare Part D changes will hit its U.S. sales, reducing revenue by about $15–$30 million. The analyst expects it will take time for the business to regain momentum.
As a result, revenue projections for 2025 have been lowered, affecting longer-term estimates. The firm remains cautious, awaiting clearer signs of growth from the company&#8217;s pipeline, existing drugs, or business development. Needham <a href="https://www.benzinga.com/quote/BIIB/analyst-ratings" target="_blank" rel="noreferrer noopener">maintains a Hold rating</a>.
HC Wainwright analyst Ananda Ghosh expects lecanemab&#8217;s growth to gain momentum once blood-based biomarkers, which could be approved in the second half of 2025, help reduce challenges related to MRI scans.
Given the guidance of a year-over-year revenue decline, the HC Wainwright analyst re-evaluates revenue estimates, given the near-term headwinds. Thus, the price target is reduced to $241 from $300, maintaining the Buy rating.
Oppenheimer analyst Jay Olson expects Leqembi and Skyclarys to boost long-term revenue, though it may take time for that growth to materialize. He also sees the Fit-for-Growth initiatives helping improve operating margins over time.
With an Outperform rating and $255 price target, Olson is optimistic about the competitive landscape, noting that evidence favors ongoing treatment rather than a fixed duration. As a result, Oppenheimer anticipates some patients may switch from donanemab to Leqembi, especially with the availability of a subcutaneous (subQ) version.
RBC Capital Markets says Biogen has effectively streamlined its research and development priorities and optimized expenses, as reflected in its fourth-quarter results and 2025 guidance, leading to a stronger core business structure.
Analyst Brian Abrahams believes Biogen&#8217;s stock is undervalued compared to its actual business fundamentals. He suggests that progress with Leqembi&#8217;s subcutaneous version or EU approvals, a pipeline success, or favorable deals could help shift investor sentiment and narrow this gap.
RBC Capital has lowered the price target to $225 from $231 with an Outperform rating.
Truist writes Leqembi&#8217;s growth remains the main focus for both Biogen and investors. While new formulations and blood-based diagnostics may support growth in 2025, they don&#8217;t anticipate significant breakthroughs.
Analyst Srikripa Devarakonda maintains the Buy rating while lowering the price target from $220 to $210.
Price Action: BIIB stock is up 4.06% at $138.85 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43696324/sap-partners-with-databricks-to-launch-business-data-cloud" target="_blank" rel="noreferrer noopener">SAP Unleashes Business Data Cloud With Smarter AI Insights: Details</a></li>
</ul>
Photo: Tada Images/Shutterstock.com

BIIB

Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts

BSLK

Bolt Projects Holdings Shares Halted On Circuit Breaker

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS – Molson Coors (TAP) up 7% GE HealthCare (GEHC)...

Morning Movers: Molson Coors rises following earnings, Deere falls

Notable gainers among liquid option names this morning include MGM Resorts (MGM) $39.09 +4.72, Caesars (CZR) $38.32 +2.72, Intel (INTC) $24.09 +1.6...

Early notable gainers among liquid option names on February 13th

BTIG raised the firm's price target on GE HealthCare (GEHC) to $103 from $99 and keeps a Buy rating on the shares following quarterly results. The ...

GE HealthCare price target raised to $103 from $99 at BTIG

In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on GE Healthcare Technologies Inc (GEHC – Research Report), with a pri...

Strong Buy Recommendation for GE Healthcare Technologies Inc. Amid Promising Financial Performance and Growth Prospects

GE HealthCare stock jumps 9% amid Q4 report, 2025 outlook

GE HealthCare Technologies Inc. (GEHC) Q4 2024 Earnings Call Transcript

GE HealthCare projects $4.61-$4.75 adjusted EPS for 2025 amid margin expansion and Flyrcado launch

GE HealthCare Technologies Inc. 2024 Q4 - Results - Earnings Call Presentation

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Cisco (CSCO) increased revenue 9% year...

Cisco jumps after earnings beat, Trump teases reciprocal tariffs: Morning Buzz

Citi raised the firm's price target on GE HealthCare (GEHC) to $110 from $103 and keeps a Buy rating on the shares. Operating margins expanded "sig...

GE HealthCare price target raised to $110 from $103 at Citi

AAPL

AMZN

ASPN

ATAI

ATUS

BPAQF

BROS

CYBR

DDOG

HNDAF

TSLA

YETI

Press Releases

GE HealthCare to announce fourth quarter and full year 2024 results on February 13, 2025

Sutter Health and GE HealthCare enter strategic partnership to benefit patients, physicians and clinicians with advanced, AI-powered imaging

University of California San Francisco and GE HealthCare Launch a Joint Research Program to Drive Innovations in Imaging, Brain Health and Precision Oncology

GE HealthCare unveils enhanced Voluson Expert Series women's health ultrasound systems with focus on early detection and exam efficiency

GE HealthCare named to 2025 Fortune World's Most Admired Companies™ list

Small Cap

Opinion

Potential Revolution in Healthcare Brewing, Powered by AI Innovation

GE HealthCare Invests $138 Million in Cork, Ireland Manufacturing Facility to Address Increasing Contrast Media Demand

GE HealthCare management to present at upcoming investor conference

FDA Approval Race: AI-Powered Innovations Reshape the Healthcare Landscape

GE HealthCare reports fourth quarter and full year 2024 financial results

ABSI

AVAI

MDAI

MRNA

TDOC

TREN

Abbott Laboratories

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Medtronic

Inari Medical

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings

Jefferies

Wells Fargo

Evercore ISI Group

Stifel

GE HealthCare Technologies shares are trading higher after the company reported better-than-expected Q4 adjusted EPS results and issued FY25 adjusted EPS guidance with its midpoint above estimates.

Comments

GE HealthCare Techs

Noticias

Últimas noticias sobre GE HealthCare Techs (NASDAQ:GEHC) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL